Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Perceptive Instruments Earn Out Payment

13 Feb 2015 07:00

RNS Number : 8002E
Instem plc
13 February 2015
 



13 February 2015

Instem plc("Instem" or the "Company")

 

Perceptive Instruments Earn Out Payment

 

Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces that it has paid in full the performance based earn out of £300,000 in respect of the acquisition of Perceptive Instruments Limited ('Perceptive').

 

Earn Out Payment

As a result of Perceptive achieving all of the specified earn out targets for the period to 21 November 2014, the Vendors have been paid the maximum additional consideration of £300,000 in accordance with the Acquisition Agreement.

 

Background to the Acquisition

Instem acquired Perceptive in November 2013 for a maximum consideration of £1.3m, including the conditional earn out, marking the Company's entrance into the in vitro R&D marketplace.

 

Perceptive is located in Suffolk, UK, and develops, manufactures and supplies software and hardware products for in vitro study data collection and study management in the genetic toxicology, microbiology and immunology markets. Perceptive is the leading technology provider within its niche market and there are few competitors active in the space.

 

Phil Reason, CEO of Instem, said: "The acquisition of Perceptive has been a success, not only in terms of the financial contribution the acquisition has made to date, but also in terms of expanding the Company's offering into the in vitro data collection and study management in the genetic toxicology, microbiology and immunology markets We are looking forward to another strong contribution from this area in 2015 and beyond."

 

For further information, please contact:

Instem plc

Tel: +44 (0) 1785 825 600

Phil Reason, CEO

www.instem.com

Nigel Goldsmith, CFO

 

 

 

N+1 Singer (Nominated Adviser & Broker)

Tel: +44 (0) 20 7496 3000

Richard Lindley

 

Nick Owen

 

 

 

Walbrook PR Ltd

Tel: +44 (0) 20 7933 8780 or

Paul Cornelius

instem@walbrookpr.com

Sam Allen

 

Nick Rome

 

 

 

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market, delivering compelling solutionsfor data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.

 

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

 

Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.

 

To learn more about Instem solutions and its mission, please visit www.instem.com

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAKAAFSDSEFF
Date   Source Headline
15th Nov 20191:10 pmRNSCompletion of the Acquisition of Leadscope
15th Nov 20197:00 amRNSEarnings Enhancing Acquisition of Leadscope
16th Oct 20197:00 amRNSInformatics Update: Progressive Equity Note
1st Oct 201910:20 amRNSHolding(s) in Company
27th Sep 201912:45 pmRNSHolding(s) in Company
23rd Sep 20197:00 amRNSHalf-year Report
13th Sep 20197:00 amRNSNotice of Results
15th Jul 20197:00 amRNSHalf Year Trading Update
3rd Jun 20195:06 pmRNSDirector/PDMR Shareholding
31st May 20197:37 amRNSHolding(s) in Company
24th May 20195:03 pmRNSDirector/PDMR Shareholding
23rd May 201911:26 amRNSResult of AGM
2nd May 20194:47 pmRNSPosting of Annual Report & Notice of AGM
29th Apr 20197:00 amRNSExercise of Options and Total Voting Rights
26th Apr 201910:59 amRNSHolding(s) in Company
18th Apr 20192:06 pmRNSSecond Price Monitoring Extn
18th Apr 20192:00 pmRNSPrice Monitoring Extension
15th Apr 20196:03 pmRNSHolding(s) in Company
15th Apr 20195:00 pmRNSHolding(s) in Company
12th Apr 20193:46 pmRNSHolding(s) in Company
12th Apr 201911:58 amRNSHolding(s) in Company
12th Apr 201911:52 amRNSHolding(s) in Company
12th Apr 20197:36 amRNSHolding(s) in Company
11th Apr 20199:49 amRNSResult of Secondary Placing
11th Apr 20197:00 amRNSProposed Placing to Sell 1,660,000 Shares
8th Apr 20196:01 pmRNSHolding(s) in Company
4th Apr 20191:48 pmRNSHolding(s) in Company
1st Apr 20197:00 amRNSFinal Results
20th Mar 20197:00 amRNSNotice of Results
1st Mar 20195:50 pmRNSHolding(s) in Company
1st Mar 20197:00 amRNSHolding(s) in Company
28th Feb 201910:35 amRNSIssue of Equity and Total Voting Rights
20th Feb 20191:44 pmRNSExercise of Options, PDMR Dealing and TVR
19th Feb 20192:09 pmRNSDirector/PDMR Shareholding
22nd Jan 20197:00 amRNSTrading Update
7th Dec 20183:28 pmRNSHolding(s) in Company
2nd Oct 20187:00 amRNSExercise of Options and Total Voting Rights
24th Sep 20187:00 amRNSHalf-year Report
10th Sep 20187:00 amRNSNotice of Results
6th Aug 20181:39 pmRNSHolding(s) in Company
23rd Jul 20187:00 amRNSTrading Update
6th Jun 20187:00 amRNSContract win
24th May 201810:43 amRNSResult of AGM
16th May 20183:18 pmRNSNotice of AGM
26th Mar 20187:01 amRNSSEND Contract Extension and SEND Update
26th Mar 20187:00 amRNSFinal Results
16th Mar 20187:00 amRNSNotice of Results
12th Mar 20189:33 amRNSIssue of Equity and TVR
7th Mar 20187:00 amRNSSaaS Business Update
26th Feb 20187:00 amRNSGrants to Directors under the Instem LTIP

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.